Alanine Transaminase (ALT): Understanding Your Blood Test Series

1. Overview: What this test reveals and why it is important

Alanine transaminase (ALT), formerly known as serum glutamic‑pyruvic transaminase (SGPT), is an enzyme concentrated primarily in the liver. It catalyses the transfer of amino groups between alanine and alpha‑ketoglutarate, a key step in gluconeogenesis and amino acid metabolism.

When liver cells are injured or die, ALT leaks into the bloodstream, causing serum levels to rise. ALT is the most specific marker of hepatocellular injury—more specific than aspartate transaminase (AST) because ALT is found predominantly in the cytoplasm of hepatocytes, whereas AST is also present in heart, muscle, kidney, and brain.

A raised ALT indicates liver cell damage, but it does not reveal the cause. The pattern of elevation (how high, how long, and in relation to AST, ALP, GGT) helps distinguish between viral hepatitis, drug injury, fatty liver, alcohol, ischaemia, and other conditions. Serial ALT measurements are used to monitor disease activity and response to treatment.

---

2. What does it measure

a. Units of measurement

· International units per litre (U/L or IU/L) – standard

b. Normal Range

(Reference intervals vary by laboratory, age, sex, and body mass index. The following are widely accepted.)

Adults:

· Men: 10–40 U/L

· Women: 7–35 U/L

Children:

· Infants and children: 10–40 U/L (slightly higher in neonates)

· Adolescents: approximate adult ranges

Elderly:

· No significant age‑related increase; stable throughout adulthood.

Pregnancy:

· ALT normally remains within non‑pregnant reference range. Mild elevation may occur in pre‑eclampsia or HELLP syndrome.

Interpretation notes:

· Values above the upper reference limit indicate hepatocellular injury.

· Mild elevation (<2 times normal) is common and often benign (e.g., NAFLD, medication effect); persistent elevation warrants investigation.

· Moderate elevation (2–5 times normal) suggests ongoing liver injury.

· Marked elevation (>5–10 times normal) indicates acute hepatitis (viral, drug, ischaemic).

· Extreme elevation (>1000 U/L) is seen in acute viral hepatitis, ischaemic hepatitis (shock liver), paracetamol toxicity, and autoimmune hepatitis flares.

· Normal ALT does not exclude liver disease; cirrhosis can present with normal enzymes.

---

3. Other factors connected to this

a. Direct correlation (factors that directly raise ALT)

Hepatocellular injury:

· Viral hepatitis: A, B, C, D, E; Epstein‑Barr virus, cytomegalovirus, herpes simplex.

· Drug‑induced liver injury: paracetamol (dose‑dependent), antibiotics (amoxicillin‑clavulanate, nitrofurantoin, isoniazid), NSAIDs, anticonvulsants, statins (rare), anti‑retrovirals, herbal supplements (kava, comfrey, green tea extract concentrates).

· Alcohol‑related liver disease: AST usually rises more than ALT (AST:ALT >1.5), but both may be elevated.

· Non‑alcoholic fatty liver disease (NAFLD): most common cause of mildly elevated ALT in developed countries; associated with obesity, insulin resistance, dyslipidaemia.

· Autoimmune hepatitis: female predominance, elevated ALT, positive autoantibodies, hypergammaglobulinaemia.

· Ischaemic hepatitis (shock liver): sudden, massive ALT rise (often >1000 U/L) after hypotension, cardiac failure, or sepsis; rapid fall with haemodynamic recovery.

· Bile duct obstruction: ALT may rise moderately (2–10 times) early in obstruction; ALP and GGT rise later and remain elevated longer.

· Hepatic ischaemia / infarction: post‑transplant, thrombotic events.

· Budd‑Chiari syndrome: hepatic vein obstruction.

· Wilson disease: ALT elevation, low ceruloplasmin, Kayser‑Fleischer rings.

· Alpha‑1 antitrypsin deficiency.

· Haemochromatosis: iron overload; ALT often normal or mildly elevated.

Extra‑hepatic causes:

· Muscle injury: strenuous exercise, trauma, polymyositis, rhabdomyolysis (ALT is present in muscle; AST and CK rise more).

· Thyroid disease: hypothyroidism may cause mild ALT elevation.

· Coeliac disease: can present with elevated ALT; resolves on gluten‑free diet.

· Haemolysis: minor effect; ALT in red cells is low.

b. Indirect correlation (factors that influence ALT interpretation)

· Age: no major effect in adults; slightly higher in adolescents.

· Sex: women have lower baseline ALT; oestrogen may be protective.

· Body mass index (BMI): ALT correlates positively with BMI and visceral adiposity. Upper reference limits are sometimes adjusted for lean populations.

· Physical activity: intense eccentric exercise can transiently elevate ALT (from muscle); AST and CK rise more.

· Circadian rhythm: slight diurnal variation; no clinical significance.

· Fasting status: prolonged fasting may lower ALT; non‑fasting samples acceptable.

· Ethnicity: Hispanic populations have higher prevalence of NAFLD and higher ALT.

· Medications: enzyme inducers (e.g., rifampicin) do not significantly raise ALT unless hepatotoxicity occurs.

· Coffee consumption: inversely associated with ALT; regular coffee drinkers have lower ALT levels.

· Insulin resistance: directly correlated with ALT independent of BMI.

· Pregnancy: ALT normally stable; elevation is pathological.

---

4. Disorders related to abnormal values

a. When elevated (hepatocellular injury pattern)

Acute hepatitis (ALT typically >5–10 times normal):

· Acute viral hepatitis (A, B, E) – ALT rises 1–2 weeks before symptoms, peaks at 1000–3000 U/L, falls over 4–8 weeks.

· Acute drug‑induced liver injury – paracetamol overdose (ALT often >1000 U/L), idiosyncratic reactions.

· Autoimmune hepatitis flare – variable; can be marked.

· Ischaemic hepatitis – ALT >1000 U/L, rapid rise and fall.

Chronic hepatitis (ALT persistently 1.5–5 times normal):

· Chronic hepatitis B or C.

· Autoimmune hepatitis.

· NAFLD / NASH.

· Alcohol‑related liver disease (AST > ALT).

· Haemochromatosis, Wilson disease, alpha‑1 antitrypsin deficiency.

Cholestatic / mixed pattern:

· Bile duct obstruction, primary biliary cholangitis, primary sclerosing cholangitis – ALT elevation usually milder than ALP/GGT.

Other:

· Coeliac disease.

· Muscle disorders (with elevated CK, AST > ALT).

· Thyroid dysfunction.

b. When low (rarely a primary concern)

· Chronic kidney disease – ALT may be falsely low due to vitamin B6 deficiency (pyridoxal‑5‑phosphate is cofactor for ALT).

· Uraemia – inhibitors in uraemic serum may reduce measured activity.

· Vitamin B6 deficiency – severe malnutrition, alcoholism.

· Advanced cirrhosis – loss of hepatocyte mass may result in normal or low ALT despite severe disease.

· Medications – some data suggest metformin, certain anticonvulsants may lower ALT.

---

5. Best way to address aberrant levels

Important principle: ALT is a marker of liver cell injury, not the injury itself. Lowering ALT means treating the underlying cause – removing the toxin, achieving viral suppression, resolving steatosis, or controlling autoimmune attack. Normalising ALT is a therapeutic goal, but it must be achieved by addressing the root disease, not by chasing the number with non‑specific hepatoprotectants.

a. Quick ways or using Medications

For specific aetiologies:

· Viral hepatitis B – oral antivirals (tenofovir, entecavir) suppress viral replication and normalise ALT in most patients. Pegylated interferon in selected cases.

· Viral hepatitis C – direct‑acting antivirals cure >95%; ALT normalises rapidly.

· Autoimmune hepatitis – corticosteroids (prednisolone) ± azathioprine; ALT improves within 2–4 weeks.

· NAFLD / NASH –

· Weight loss (5–10%) is most effective; pharmacotherapy adjunctive.

· Vitamin E (800 IU/day RRR‑alpha‑tocopherol) in non‑diabetic adults with biopsy‑proven NASH – reduces steatosis and ALT. Long‑term safety requires discussion.

· Pioglitazone – improves insulin sensitivity, steatosis, and ALT; weight gain and bone loss are limitations.

· GLP‑1 receptor agonists (liraglutide, semaglutide) – emerging evidence for NASH improvement.

· Alcohol‑related liver disease – abstinence is the only effective intervention; ALT and AST decline over weeks.

· Drug‑induced liver injury – withdraw causative agent; ALT typically improves within days to weeks.

· Ischaemic hepatitis – restore haemodynamics; ALT falls rapidly (half‑life ~48 hours).

· Haemochromatosis – phlebotomy; ALT normalises as iron stores deplete.

· Wilson disease – chelation therapy (penicillamine, trientine) or zinc acetate; ALT improvement over months.

· Coeliac disease – gluten‑free diet; ALT normalises within 3–12 months.

Do not self‑prescribe – all prescription medications for liver disease require specialist supervision.

b. Using Supplements or Holistic medicine

Important caution: Supplements are not first‑line therapy for established liver disease. They may be considered as adjuncts in NAFLD or for general liver health, but only after excluding serious aetiologies and under professional guidance. Many herbal products are themselves hepatotoxic; quality and standardisation are critical.

For elevated ALT – supporting liver health and reducing steatosis / inflammation:

· Milk thistle (Silybum marianum) –

· Silymarin has antioxidant, anti‑inflammatory, and antifibrotic properties.

· Meta‑analyses show modest ALT reduction in NAFLD and alcoholic liver disease.

· Preferred source: Standardised to 70–80% silymarin; phytosome formulations enhance bioavailability.

· Dose: 140–420 mg/day.

· Caution: Generally safe; may interact with cytochrome P450 drugs.

· Vitamin E –

· As above, for non‑diabetic NASH with biopsy confirmation.

· Use RRR‑alpha‑tocopherol (natural, plant‑derived), not synthetic dl‑alpha‑tocopherol.

· Dose: 800 IU/day.

· Do not use without medical supervision – long‑term safety concerns.

· Berberine –

· Improves insulin resistance, reduces hepatic fat, and lowers ALT in NAFLD.

· Preferred source: Standardised berberine (≥97%) from Berberis aristata or Phellodendron amurense.

· Dose: 500 mg twice daily.

· Caution: GI side effects, drug interactions (statins, cyclosporine, anticoagulants); avoid in pregnancy.

· Omega‑3 fatty acids (EPA/DHA) –

· Modest reduction in liver fat and ALT in NAFLD.

· Preferred source: Algae oil – sustainable, plant‑based, direct EPA/DHA.

· Avoid conventional fish oil (overfishing, ocean pollutants, ethical concerns).

· Dose: 2–4 g/day EPA/DHA for therapeutic effect.

· Form: re‑esterified triglyceride for optimal absorption.

· Curcumin (turmeric) –

· Anti‑inflammatory; trials show ALT reduction in NAFLD.

· Use phytosomal, liposomal, or with piperine for bioavailability.

· Avoid products with added synthetic folic acid or cyanocobalamin.

· Green tea extract (EGCG) –

· Catechins reduce oxidative stress and liver fat.

· Caution: Concentrated extracts have been linked to hepatotoxicity; use whole green tea beverage (2–3 cups/day) rather than high‑dose supplements.

· Vitamin D –

· Deficiency common in chronic liver disease; supplementation improves bone health and possibly ALT.

· Preferred: D3 (cholecalciferol) from lichen.

· Zinc –

· Deficiency common in cirrhosis and alcohol use disorder; supplementation may support liver function.

· Preferred form: zinc picolinate or citrate.

· Dose: 15–30 mg elemental zinc/day; monitor copper.

· N‑acetylcysteine (NAC) –

· Established role in paracetamol poisoning; limited evidence in chronic liver disease.

· May be used in acute liver failure under specialist care.

Ayurvedic approaches:

· Bhumi amla (Phyllanthus niruri) – hepatoprotective; used in viral hepatitis. Some evidence for ALT reduction.

· Katuki (Picrorhiza kurroa) – cholagogue, anti‑inflammatory.

· Punarnava (Boerhavia diffusa) – diuretic, anti‑inflammatory; supports liver and kidney.

· Guduchi (Tinospora cordifolia) – immunomodulatory.

· Always use standardised extracts from GMP‑certified manufacturers.

· Consult a qualified practitioner; herbs can interact with prescription drugs and some are intrinsically hepatotoxic if adulterated or misidentified.

Supplements to avoid in liver disease:

· High‑dose green tea extract – case reports of hepatotoxicity.

· Kava, comfrey, chaparral, pyrrolizidine alkaloid‑containing herbs – established hepatotoxins.

· Synthetic folic acid – no role in liver health; use methylfolate only if deficiency documented.

· Cyanocobalamin – methylcobalamin preferred if B12 needed.

c. Using Diet and Foods (following a plant‑forward, ecologically sustainable approach)

For elevated ALT – reducing liver fat and inflammation:

Core dietary pattern:

· Whole food, plant‑based (WFPB) or Mediterranean‑style plant‑forward diet – strongest evidence for improving steatosis, insulin resistance, and ALT.

· Hypocaloric diet if overweight or obese – 500–1000 kcal deficit/day. Weight loss of 5–10% is the most effective intervention for NAFLD.

· Macronutrient composition:

· Low in refined carbohydrates and added sugars – high fructose intake (especially from sugary beverages) directly promotes de novo lipogenesis.

· High in fibre (≥30 g/day) – from legumes, whole grains, vegetables, fruits, nuts, seeds.

· Moderate in unsaturated fats – extra virgin olive oil, avocados, nuts, seeds.

· Low in saturated fats, trans fats, dietary cholesterol.

· Protein sources – emphasise plant proteins; they are associated with lower NAFLD risk.

Specific foods and beverages with evidence for ALT lowering:

· Coffee – strongest and most consistent dietary factor associated with lower ALT, reduced risk of cirrhosis, and slower progression of chronic liver disease.

· 2–4 cups/day; both caffeinated and decaffeinated are beneficial.

· Mechanisms: antioxidants, inhibition of hepatic stellate cell activation, increased glutathione.

· Green tea – catechins reduce oxidative stress and hepatic fat. 2–3 cups/day; avoid concentrated extracts.

· Vegetables:

· Cruciferous (broccoli, Brussels sprouts, cabbage, cauliflower, kale) – glucosinolates support detoxification.

· Leafy greens (spinach, Swiss chard, collards, moringa) – magnesium, folate, vitamin K.

· Beetroot – betaine; may reduce hepatic steatosis.

· Fruits:

· Berries (blueberries, strawberries, blackberries) – anthocyanins, antioxidant.

· Citrus – vitamin C, naringenin.

· Legumes: lentils, chickpeas, black beans, kidney beans, soybeans – soluble fibre, plant protein.

· Whole grains: oats, barley, quinoa, brown rice, millets – beta‑glucans, magnesium.

· Nuts and seeds: walnuts (high in ALA), almonds, flaxseeds, chia seeds, hemp seeds – vitamin E, magnesium, healthy fats.

· Turmeric, ginger – anti‑inflammatory; use fresh or powdered.

· Garlic, onions – organosulfur compounds.

· Fungi: shiitake, maitake, oyster mushrooms – beta‑glucans, ergothioneine.

· Algae: spirulina, chlorella – some evidence for liver protection; acceptable as whole food.

· Olive oil – extra virgin; anti‑inflammatory, reduces steatosis.

What to avoid or severely limit:

· Alcohol – complete abstinence if any alcohol‑related liver injury; otherwise strict moderation (zero is safest for elevated ALT).

· Sugary beverages (soft drinks, fruit juices, sweetened teas) – principal source of excess fructose.

· Ultra‑processed foods – high in refined grains, added sugars, unhealthy fats, additives.

· Red and processed meats – associated with NAFLD and insulin resistance; not required.

· Excessive saturated fats – butter, cream, fatty meats, palm oil, coconut oil (use sparingly).

Protein sources (hierarchy adhered):

· Plant‑based: legumes, soy products (tofu, tempeh, edamame), seitan – primary.

· Fungi / algae: mycoprotein (Quorn), spirulina, chlorella – encouraged.

· Biotechnology / lab‑grown: precision‑fermented dairy proteins, heme analogues – acceptable emerging options.

· Dairy / eggs: permitted but not emphasised; full‑fat dairy may contribute to NAFLD; low‑fat fermented dairy (yoghurt, kefir) less detrimental.

· Meat, poultry, fish: deliberately omitted. There is no nutritional requirement for meat to achieve normalisation of ALT. All dietary needs for liver health can be met with plant‑based sources plus targeted supplementation (vitamin B12, vitamin D from lichen, algae omega‑3) when indicated.

---

6. How soon can one expect improvement and the ideal time frame to retest

For acute hepatitis (viral, drug, ischaemic):

· ALT begins to fall within 24–72 hours after removal of insult (drug, ischaemia) or with supportive care.

· Complete normalisation in uncomplicated cases: 2–4 weeks.

· Retest: weekly until downward trend established, then every 2–4 weeks until normal.

For NAFLD:

· Weight loss of 5%: ALT improvement detectable in 3–6 months.

· Weight loss of 10% or more: significant ALT reduction or normalisation in 6–12 months.

· Dietary change alone: ALT improvement in 8–12 weeks with consistent adherence to plant‑based, low‑glycaemic, hypocaloric diet.

· Retest: every 3–6 months during active intervention.

For alcoholic liver disease:

· Abstinence: ALT declines with a half‑life of approximately 2–4 weeks; normalisation in 2–3 months.

· Retest: at 4–6 weeks, then every 3 months.

For autoimmune hepatitis on immunosuppression:

· ALT improves within 2–4 weeks of starting corticosteroids; normalisation by 3–6 months.

· Retest: frequent initially (2–4 weeks), then every 3–6 months.

For chronic hepatitis B on antivirals:

· ALT normalises in 3–6 months in most patients; delayed response possible.

· Retest: at 3 months, then every 3–6 months.

For chronic hepatitis C after curative DAA therapy:

· ALT normalises by end of treatment (8–12 weeks) or soon after.

· Retest: at sustained virologic response (SVR12) visit.

For drug‑induced liver injury (non‑paracetamol):

· After stopping drug, ALT improves over 2–8 weeks depending on half‑life.

· Retest: 1–2 weeks initially, then monthly until normal.

Retesting interval summary:

· Mild, asymptomatic elevation: repeat in 4–6 weeks with fasting sample, full liver panel, GGT, and NAFLD risk assessment.

· Confirmed NAFLD on lifestyle intervention: every 3–6 months.

· Chronic liver disease on treatment: every 3–6 months initially, then 6–12 months when stable.

· Acute hepatitis: as directed by specialist; often weekly to monthly.

---

Conclusion

Alanine transaminase is the liver's distress signal—a leak from wounded hepatocytes. An elevated ALT is never the disease itself; it is the laboratory echo of hepatitis, steatosis, toxins, ischaemia, or immune attack. To lower ALT is to heal the liver, and that requires a precise diagnosis and targeted therapy.

For the millions with fatty liver—the modern epidemic—the prescription is not found in a bottle. It is written in the kitchen and the gym: whole plants, not ultra‑processed fractions; legumes, not livestock; coffee, not soft drinks; movement, not sedentarism. Weight loss of 5–10% is more powerful than any drug.

When drugs are needed—antivirals, immunosuppressants, insulin sensitizers—they are highly effective. When supplements are considered as adjuncts—silymarin, berberine, vitamin E, algae omega‑3—they must be chosen in active, bioavailable forms, free from synthetic additives, and never as substitutes for definitive treatment.

We omit meat from these recommendations because it is clinically unnecessary and ecologically unsustainable. A well‑planned plant‑based diet, fortified with methylcobalamin and lichen‑derived vitamin D, meets every nutritional demand of the recovering liver.

ALT is a number. The liver is an organ. The patient is a person. Treat the person, not the number—but when the number is high, investigate, intervene, and persist.

---x---x

Note on dietary recommendations on this site:

For the sake of our environment we adhere to the following dietary preference hierarchy:

1. Plant‑based

2. Fungi / algae / fermented

3. Biotechnology / lab‑grown / cultures

4. Dairy / eggs

5. Meat / fish / poultry (only if no effective alternative exists)

This approach reflects ecological responsibility, antibiotic stewardship, and the urgent need to reduce the environmental footprint of dietary recommendations.

-x-x